BlossomHill Therapeutics Q2 Loss Widens

07:42 AM EDT, 09/18/2026 (MT Newswires) -- BlossomHill Therapeutics (BLSM) reported a Q2 loss on Friday of $8.75 per share, widening from a loss of $5.51 a year earlier. One analyst polled by FactSet expected a GAAP loss of $0.77. The company did not report any revenue for the quarter. Cash and cash equivalents for the quarter ended June 30 totaled $95.4 million, which, together with proceeds from its recent IPO, should be sufficient to fund operations into Q2 2028, the company said.